SCYNEXIS Future Growth
Future criteria checks 5/6
SCYNEXIS is forecast to grow earnings and revenue by 48.7% and 30.8% per annum respectively while EPS is expected to grow by 49.2% per annum.
Key information
48.7%
Earnings growth rate
49.2%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 30.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop
Jun 19SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 12SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 111 | 65 | 17 | 40 | 4 |
12/31/2025 | 53 | 8 | N/A | 12 | 4 |
12/31/2024 | 10 | -22 | N/A | -14 | 4 |
9/30/2024 | 9 | -36 | -22 | -22 | N/A |
6/30/2024 | 10 | -35 | -10 | -10 | N/A |
3/31/2024 | 140 | 101 | 75 | 75 | N/A |
12/31/2023 | 140 | 67 | 60 | 60 | N/A |
9/30/2023 | 136 | 72 | 45 | 45 | N/A |
6/30/2023 | 136 | 44 | 10 | 10 | N/A |
3/31/2023 | 6 | -91 | -83 | -83 | N/A |
12/31/2022 | 5 | -63 | -80 | -80 | N/A |
9/30/2022 | 4 | -78 | -83 | -83 | N/A |
6/30/2022 | 3 | -49 | -78 | -77 | N/A |
3/31/2022 | 2 | -34 | -71 | -70 | N/A |
12/31/2021 | 13 | -33 | -56 | -55 | N/A |
9/30/2021 | 13 | -46 | -46 | -46 | N/A |
6/30/2021 | 12 | -45 | -39 | -39 | N/A |
3/31/2021 | 12 | -53 | -36 | -36 | N/A |
12/31/2020 | N/A | -55 | -49 | -49 | N/A |
9/30/2020 | N/A | -27 | -46 | -46 | N/A |
6/30/2020 | N/A | -36 | -47 | -47 | N/A |
3/31/2020 | 0 | -38 | -46 | -46 | N/A |
12/31/2019 | 0 | -54 | -38 | -38 | N/A |
9/30/2019 | 0 | -37 | -31 | -31 | N/A |
6/30/2019 | 0 | -29 | -27 | -26 | N/A |
3/31/2019 | 0 | -31 | -27 | -27 | N/A |
12/31/2018 | 0 | -12 | -29 | -28 | N/A |
9/30/2018 | 0 | -22 | -28 | -27 | N/A |
6/30/2018 | 0 | -31 | N/A | -27 | N/A |
3/31/2018 | 0 | -24 | N/A | -26 | N/A |
12/31/2017 | 0 | -25 | N/A | -25 | N/A |
9/30/2017 | 0 | -21 | N/A | -24 | N/A |
6/30/2017 | 0 | -24 | N/A | -26 | N/A |
3/31/2017 | 0 | -28 | N/A | -27 | N/A |
12/31/2016 | 0 | -30 | N/A | -29 | N/A |
9/30/2016 | 0 | -35 | N/A | -31 | N/A |
6/30/2016 | 0 | -31 | N/A | -30 | N/A |
3/31/2016 | 0 | -30 | N/A | -29 | N/A |
12/31/2015 | 0 | -28 | N/A | -25 | N/A |
9/30/2015 | 1 | -23 | N/A | -20 | N/A |
6/30/2015 | 1 | -19 | N/A | -18 | N/A |
3/31/2015 | 1 | -11 | N/A | -14 | N/A |
12/31/2014 | 1 | -7 | N/A | -9 | N/A |
9/30/2014 | 4 | -42 | N/A | -9 | N/A |
6/30/2014 | 8 | -43 | N/A | -6 | N/A |
3/31/2014 | 12 | -47 | N/A | -2 | N/A |
12/31/2013 | 17 | -47 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: SCYX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SCYX is expected to become profitable in the next 3 years.
Revenue vs Market: SCYX's revenue (30.8% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: SCYX's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time